Antiangiogenic Drugs (VEGF Inhibitors): — How Starving a Tumour Works
VEGF inhibitors work by blocking a protein that tells the body to grow new blood vessels into a tumour. Cutting off that supply is the goal — and it is used in kidney, colorectal, liver, lung, thyroid, and gastric cancers, either alone or alongside chemotherapy or immunotherapy.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
- The target is the blood supply — Tumours cannot grow beyond a small size without recruiting new blood vessels. VEGF inhibitors block the signal that starts that process.
- Two types of drug — Monoclonal antibodies bind to the VEGF protein directly. Tyrosine kinase inhibitors (TKIs) block the receptor on blood vessel cells that VEGF would normally switch on.
- Used across many cancers — NCCN and ASCO guidance includes antiangiogenic drugs in standard treatment pathways for kidney, colorectal, liver, lung, thyroid, and gastric cancers, among others.
- Different side effects from chemotherapy — Hair loss is uncommon. High blood pressure and slower wound healing are more typical of this drug class.
on Panel
Survival Rate*
Treated
(800+ reviews)
VEGF inhibitors block a protein called vascular endothelial growth factor, which tumours use to grow new blood vessels. Without that supply, the tumour is starved of nutrients. These drugs are used in kidney, colorectal, liver, lung, thyroid, and gastric cancers, among others, and are named in NCCN and ASCO treatment guidelines for each.
How do VEGF inhibitors cut off a tumour's blood supply?
Every tumour beyond a small size needs a blood supply to survive. To build one, tumour cells release a protein called VEGF — vascular endothelial growth factor — which signals nearby blood vessel cells to grow towards the tumour and feed it.
VEGF inhibitors interrupt that signal. Some, called monoclonal antibodies, bind to the VEGF protein in the bloodstream before it can reach its target. Others, called tyrosine kinase inhibitors or TKIs, block the receptor on blood vessel cells that VEGF would normally switch on.
Without a new blood supply, the tumour is starved of nutrients and oxygen. This does not destroy the tumour directly — it slows or constrains growth, which is why these drugs are most often used alongside other treatments rather than alone.
Which cancers are VEGF inhibitors used for?
NCCN and ASCO guidance includes antiangiogenic drugs in standard treatment pathways for several cancers. The specific drug is chosen based on cancer type, prior treatment history, and kidney and liver function — not on VEGF testing of the tumour tissue.
In kidney cancer (renal cell carcinoma): sunitinib, pazopanib, axitinib, and cabozantinib are established options across different lines of treatment. In colorectal cancer: bevacizumab is used alongside chemotherapy. In liver cancer (hepatocellular carcinoma): sorafenib, lenvatinib, and regorafenib are used at different stages of disease.
In non-small cell lung cancer: bevacizumab is used in certain subtypes alongside chemotherapy. In thyroid cancer: lenvatinib, sorafenib, and cabozantinib are used when disease no longer responds to radioiodine. In gastric cancer: ramucirumab is an established second-line option per ESMO and ASCO guidance.
Your oncologist selects the right drug for your specific situation. These are prescription medicines given as part of a supervised treatment plan.
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Dr. Mohammed Imran
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
What side effects should you watch for?
The side effect profile differs from chemotherapy. Hair loss is uncommon. Instead, effects reflect what VEGF normally does in healthy tissue — it maintains blood vessel walls, supports wound healing, and helps regulate blood pressure.
High blood pressure is the most common side effect across this drug class. ASCO guidance recommends monitoring blood pressure throughout treatment. Tell your team immediately if you develop severe headaches, blurred vision, or chest heaviness — these can signal a blood pressure level that needs urgent attention.
Wound healing slows on antiangiogenic drugs. If you need any procedure or surgery, tell your oncologist before it is scheduled. With TKIs specifically, you may notice redness and soreness on the palms or soles — hand-foot syndrome. Report it early so your team can adjust the dose before it becomes severe.
What does starting antiangiogenic treatment look like?
Baseline checks
Before you start, your team checks blood pressure, kidney function, liver function, and urine protein. They also review every medicine and supplement you take, because some interact with VEGF inhibitors.
Choosing the drug
Your oncologist selects the specific drug based on your cancer type, treatment history, and overall health. Monoclonal antibodies are given as intravenous infusions at the clinic. Most TKIs are daily tablets taken at home.
Starting treatment
Infusions are given as day care — you come in, receive the infusion over a set time, and go home the same day. Tablets are taken as directed, usually at the same time each day, with instructions on whether to take them with food.
Ongoing monitoring
Blood pressure is checked at visits and you may be asked to monitor it at home. Blood tests look at kidney and liver function. You will be asked about side effects each time you come in.
Response assessment
After a set number of cycles, a CT scan or other imaging is done to assess whether the tumour is responding. Your oncologist reviews the result and discusses what it means for the next phase of treatment.
Questions families commonly ask
Will I feel as sick as I would on chemotherapy?
The side effect profile is different, not necessarily easier. Nausea and hair loss are uncommon with VEGF inhibitors, but fatigue, high blood pressure, and effects on wound healing are frequent. Some people tolerate these drugs well and continue working; others find fatigue a significant challenge. The specific drug matters — TKIs taken daily as tablets tend to produce more consistent low-grade side effects, while infusion-based antibodies cause reactions around infusion days. Your team can tell you what is most common with the specific drug you are starting.
Can I have surgery while on a VEGF inhibitor?
Antiangiogenic drugs significantly slow wound healing and increase bleeding risk. For any planned surgery, your oncologist will advise pausing treatment in the weeks before and after the procedure. The exact timing depends on which drug you are on and what operation is planned. Do not agree to any procedure — including a dental extraction or endoscopy — without telling both your surgeon and your oncologist, so they can coordinate. If emergency surgery is ever needed, the surgical team should be told immediately that you are on this class of drug.
How do I take the tablet form correctly at home?
Most TKIs are taken once or twice daily, at the same time each day. Some must be taken with food and some without — follow the specific instruction for your drug, because this affects how much reaches your bloodstream. Do not halve, crush, or chew tablets unless your team has confirmed it is safe. If you miss a dose, follow your team's guidance — the rule varies by drug. Never double the next dose to compensate for a missed one. Keep tablets in their original packaging, away from heat and moisture, and out of reach of children.
What happens if my blood pressure goes very high?
High blood pressure on VEGF inhibitors is common and manageable when caught early. Your team may start or adjust blood pressure medicine when treatment begins. The danger is pressure that rises rapidly to very high levels without being detected — this can rarely lead to a hypertensive crisis. Severe headache, visual changes, confusion, or chest pain during treatment are reasons to seek emergency assessment the same day, not to wait for your next appointment. Most people on these drugs are asked to check blood pressure at home and keep a simple log to share at each visit.
Are there foods or supplements I should avoid?
Yes. Grapefruit and grapefruit juice interact with several TKIs by affecting how the drug is broken down in the liver — it can raise drug levels to an unsafe range. Avoid grapefruit entirely while on these medicines unless your team explicitly says it is safe for your specific drug. Herbal supplements, including traditional remedies, can also interact — some affect the same liver enzymes. Tell your oncologist about everything you take, including Ayurvedic or homeopathic preparations, before starting. The purpose of that conversation is to make your treatment as safe as possible.
How long will treatment continue?
VEGF inhibitors are generally continued for as long as the tumour is responding and side effects remain manageable. There is usually no fixed number of cycles set in advance. Your oncologist reassesses with imaging at intervals and discusses the result with you. If the tumour begins to grow despite treatment, or if side effects become unacceptable, the plan will change — to a different drug in the same class, or to a different approach entirely. Some people stay on these drugs for months to years; others change after a few cycles. Your own response is what guides the decision.
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Frequently asked questions
What exactly is VEGF and why does it matter in cancer?
VEGF stands for vascular endothelial growth factor. It is a protein that signals blood vessel cells to grow — a process called angiogenesis. In normal tissue it helps wounds heal and organs develop. In cancer, tumour cells hijack this process, releasing VEGF to recruit a blood supply that feeds their growth. Without that supply, most tumours cannot grow beyond a small size. VEGF inhibitors are designed to block this recruitment signal at different points in the pathway.
How is an antiangiogenic drug different from chemotherapy?
Chemotherapy targets rapidly dividing cells — which includes cancer cells, but also hair follicles and the gut lining, causing hair loss and nausea. Antiangiogenic drugs target blood vessel formation rather than dividing cells directly, so the side effect profile is different. Hair loss is uncommon. Instead, effects include high blood pressure, slower wound healing, and fatigue. Neither class is inherently milder — the effects are different, and which matters more depends on your specific cancer and overall health.
Which VEGF inhibitor will I be given?
The choice depends on your cancer type, the stage of disease, your prior treatment history, and your kidney and liver function. There is no single best drug across all cancers — NCCN and ASCO guidance lists specific drugs for specific cancers and lines of treatment, and your oncologist follows that evidence. If you want to understand why a particular drug was chosen for your situation, that is a reasonable question to ask at your appointment.
How soon do VEGF inhibitors start working?
There is no reliable sign of activity in the first few days of treatment. The first formal assessment is usually imaging — a CT scan — done after a set number of weeks or cycles. Some people notice changes in symptoms before imaging confirms a response; others notice no change in how they feel even when imaging shows the tumour is stable or shrinking. Neither pattern alone is a reliable guide to whether treatment is working. Wait for the imaging result and discuss it with your oncologist before drawing conclusions.
Can I continue working during treatment?
Many people do, particularly when side effects are well managed. The main challenges are fatigue, which varies widely between individuals and drug types, and the need to monitor blood pressure and attend regular appointments. TKIs taken at home as daily tablets offer more scheduling flexibility than regular infusion visits. Whether you can continue working depends on the demands of your job, how you respond to the specific drug, and whether your employer can accommodate adjustments. Discuss it with your oncologist before making decisions — they can give you a realistic picture of what to expect in the first weeks.
What happens if the treatment stops working?
If imaging shows the tumour growing despite treatment, your oncologist will discuss the available options. For several cancers there are second- and third-line VEGF inhibitors or other drug classes used after the first treatment stops working — in kidney cancer, for example, NCCN guidance lists multiple sequential options. Whether switching to another drug in the same class makes sense, or whether a different approach is better, depends on your cancer type, your overall health, and the evidence for your specific situation. Stopping one treatment does not mean running out of options, and your oncologist should explain what is available and what each is realistically expected to achieve.